Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation

NCT02044874 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT02044874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02044874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
November 30, 2014
Enrollment
603 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation